DENVER, Colo., Oct 26, 2023 (www.247marketnews.com)- ABVC BioPharma, Inc. (NASDAQ: ABVC) stated this morning, that it entered into a binding term sheet regarding a multi-year, global licensing agreement with AiBtl BioPharma for the Company’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the “Licensed Products”). The potential license will cover the Licensed Products’ clinical trial, registration, manufacturing, supply, and distribution rights.
ABVC BioPharma is trading at $1.33, up $0.48 (+56.47%), on 429.9K premarket shares traded.
Its 52-week range is $0.6739 to 18.70. It hit a new 52-week low on the 6th and today’s volume is easily its largest volume day in months, so this is potentially set to make a very strong move, especially if it catches enough shorts off guard.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.